Research programme: atherosclerosis/lipid metabolism disorders therapeutics - AbbVie/GenfitAlternative Names: SOL-02
Latest Information Update: 22 Jan 2013
At a glance
- Originator Genfit; Laboratoires Fournier
- Developer AbbVie; Genfit
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Atherosclerosis; Lipid metabolism disorders